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a b s t r a c t
Antiviral immunity is initiated upon host recognition of viral products via non-self molecular patterns
known as pathogen-associated molecular patterns (PAMPs). Such recognition initiates signaling cascades
that induce intracellular innate immune defenses and an inﬂammatory response that facilitates
development of the acquired immune response. The retinoic acid-inducible gene I (RIG-I) and the
RIG-I-like receptor (RLR) protein family are key cytoplasmic pathogen recognition receptors that are
implicated in the recognition of viruses across genera and virus families, including functioning as major
sensors of RNA viruses, and promoting recognition of some DNA viruses. RIG-I, the charter member of
the RLR family, is activated upon binding to PAMP RNA. Activated RIG-I signals by interacting with the
adapter protein MAVS leading to a signaling cascade that activates the transcription factors IRF3 and
NF-κB. These actions induce the expression of antiviral gene products and the production of type I and III
interferons that lead to an antiviral state in the infected cell and surrounding tissue. RIG-I signaling is
essential for the control of infection by many RNA viruses. Recently, RIG-I crosstalk with other pathogen
recognition receptors and components of the inﬂammasome has been described. In this review, we
discuss the current knowledge regarding the role of RIG-I in recognition of a variety of virus families and
its role in programming the adaptive immune response through cross-talk with parallel arms of the
innate immune system, including how RIG-I can be leveraged for antiviral therapy.
& 2015 Elsevier Inc. All rights reserved.
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Introduction
The innate immune response provides the ﬁrst line of defense
against virus infection. The innate immune system of vertebrates is
multi-pronged and highly differentiated. Cell-associated proteins
known as pathogen recognition receptors (PRRs) recognize non-self
molecular patterns known as pathogen-associated molecular pat-
terns (PAMPs). PAMPs are viral products, including protein, protein/
lipid complexes, and viral nucleic acid, that are speciﬁc to the virus or
aberrantly located within the cell and typically accumulate during
infection. During virus infection PAMPs accumulate at various sites
within the infected cell, including at the cell surface, inside endoso-
mal compartments, or free in the cell cytosol. PAMP engagement and
activation of PRRs initiate intracellular signaling cascades leading to
the expression of genes whose products function to restrict virus
replication and spread, attract innate immune cells to the site of
infection and induce their antiviral activity, and modulate the
adaptive immune response to the viral infection. Secretion of
chemokines and cytokines, including type 1 and 3 interferon (IFN),
from the infected cell acts to warn neighboring cells of the threat and
to attract immune cells from elsewhere in the body to the site of
infection. Based on the signals received by the components of the
innate and adaptive immune responses, the invading pathogen will
be either attacked or tolerated. Programming the immune response
against viral infection is highly dependent on nonself discrimination
of PAMP versus self molecular patterns found within healthy cells.
Aberrant recognition and innate immune signaling induced by self
molecular patterns have important consequences that can impart
autoimmune disease. Thus, tight regulation of the innate immune
response is necessary to maintain immune homeostasis while
allowing for quick and robust control of viral infection.
Mammalian PRRs are categorized according to ligand speciﬁcity,
function, localization and/or evolutionary and structural relationship.
PRRs can be secreted, membrane bound, or cytoplasmic proteins.
Examples of secreted PRRs include the mannose-binding lectin (MBL)
and ﬁcolin which recognize D-mannose and L-fucose carbohydrate
residues on a range of microbes including viruses to initiate the
complement pathway, a major arm of the host innate immune
response (Matsushita, 2010; Murphy et al., 2008). These secreted PRRs
are not involved in intracellular signaling cascades but instead trigger
soluble protease cascades to complement activation in the blood.
Membrane-bound PRRs include the Toll-like receptors (TLRs), which
are found on the cell surface or within endosomal compartments in
most cells of the body, and C-type lectin receptors which are typically
found on dendritic cells or macrophages (Murphy et al., 2008). TLRs
recognize a variety of PAMPs relevant to virus infection including
unmethylated CpG DNA found in the genome of DNA viruses (TLR9),
and double-stranded (ds) or single-stranded (ss) RNA viral products
recognized by TLR3 and TLR7/8, respectively (Kawai and Akira, 2010).
Cytoplasmic PRRs include NOD-like receptors (NLRs) (Ye and Ting,
2008), the cytosolic DNA sensor cyclic GMP-AMP synthase (cGAS) (Cai
et al., 2014), and RIG-I-like receptors (RLRs) (Loo and Gale, 2011). NLRs
recognize a wide range of PAMPs and DAMPs (damage-associated
molecular patterns produced form damaged host cells). There are
several NLR family members, each involved in recognizing intracellular
PAMPs or DAMPs that accumulate in response to virus infection. NLR
signaling results in formation of the inﬂammasome, a multicompo-
nent protein complex that catalyzes the downstream processing and
activation of latent caspase 1 zymogen and its cleavage and cellular
release of pro-IL-1β family members to induce an inﬂammatory
cascade (Wen et al., 2013). cGAS is a recently described cytosolic
dsDNA sensor that catalyzes the formation of a heterocyclic dinucleo-
tide, cGAMP (Sun et al., 2013; Xiao and Fitzgerald, 2013; Zhang et al.,
2013). cGAMP binding to the adapter protein STING located on
intracellular membranes initiates TBK-1 phosphorylation and IRF3
activation (Shu et al., 2014). Although cGAS senses dsDNA during DNA
virus infection, recent reports have implicated this pathway in the
sensing of RNA viruses as well (Maringer and Fernandez-Sesma, 2014;
Schoggins et al., 2014). RIG-I-like receptors (RLRs) include the cytosolic
PRRs retinoic acid-induced gene I (RIG-I), melanoma differentiation-
associated gene 5 (MDA5) and laboratory of genetics and physiology 2
(LGP2). In particular, RIG-I is the subject of this review and is described
in detail in the following sections. All three RLRs share a common
structure which includes a DExD/H-box helicase domain and a
C-terminal domain known as the repressor domain (RD). RIG-I and
MDA5 also contain N-terminal tandem caspase activation and recruit-
ment domains (CARDs) that function in signaling, which LGP2 lacks.
Activation of MDA5 or RIG-I leads to interactions of the CARDs with
the CARD of the mitochondrial activator of virus signaling (MAVS)
protein, the essential signaling adapter protein of the RLRs (also
known as IPS-1, VISA, or Cardif) (Kawai et al., 2005; Meylan et al.,
2005; Xu et al., 2005). CARD–CARD interactions result in initiation of a
signaling cascade that includes activation of TBK1 and IKKε protein
kinases which phosphorylate and activate the transcription factors
interferon regulatory factor (IRF) 3 and NF-κB. Recruitment of tumor
necrosis factor receptor type 1-associated death domain protein
(TRADD), Fas-associated protein with death domain (FADD), recep-
tor-interacting protein 1 (RIP1), caspase-8 and caspase-10 leads to
activation of the IKK complex consisting of IKKα, IKKβ, and IKKγ,
which in turn activate NF-κB (Kawai et al., 2005; Takahashi et al.,
2006). Upon activation, IRF3 and NF-κB translocate from the cytosol to
the nucleus to induce transcription of a variety of innate immune
response genes, including IFNs, direct antiviral genes, and pro-
inﬂammatory genes whose products orchestrate the innate immune
response to infection. IFNs then induce hundreds of interferon-
stimulated genes (ISGs) whose products have antiviral, immunomo-
dulatory, cell growth regulatory, and metabolic regulatory actions that
create an antiviral state. If successful, this response potently restricts
virus replication and cell-to-cell spread of infection. However, many, if
not all, pathogenic viruses possess strategies to evade the innate
immune response and thus cause disease (Chiang et al., 2014).
RIG-I activation and regulation
RIG-I is expressed at a low level in most cells of the body and its
abundance increases in response to IFN. In non-infected cells RIG-I is
found in a resting state with the RD covering the RNA-binding and
helicase domains (Saito et al., 2007). CARDs of ‘resting’ RIG-I are also
folded over one another with these interactions governing the signaling
activity of RIG-I (Fig. 1(1)) (Kowalinski et al., 2011). Following recogni-
tion of PAMP RNA, RIG-I hydrolyzes ATP and undergoes a conforma-
tional change which opens the RNA binding domain for closer
interaction with PAMP RNA while releasing the CARDs for MAVS
interaction and signaling (Fig. 1(2)) (Jiang et al., 2011; Kowalinski et
al., 2011). The hydrolysis of ATP also facilitates translocation of RIG-I
along the RNA, thus making room for other RIG-I proteins to
oligomerize onto the PAMP molecule (Patel et al., 2013). RIG-I is then
modiﬁed with ubiquitin at N-terminal sites by the TRIM25 protein thus
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allowing CARD–CARD tetramers to form in the presence of ubiquitin
(Gack et al., 2007, 2008). For sustained activation, RIG-I interacts with
the dsRNA binding protein PACT, which binds to the C-terminal domain
of RIG-I aiding in ATP hydrolysis to maintain the protein in an active
state (Kok et al., 2011). Interactions with zinc antiviral protein short
isoform (ZAPS) also maintain RIG-I in an activated state (Hayakawa et
al., 2011). As shown in Fig. 1, the entire complex then translocates from
the cytoplasm to the mitochondrial associated membrane (MAM)
facilitated by the 14-3-3ε protein to chaperone the RIG-I ‘translocase’
to the MAM (Liu et al., 2012). At the MAM, RIG-I CARDs interact with
the MAVS CARD, catalyzing ﬁlament formation of MAVS which in turn
activates TBK1 and IKKε to initiate downstream signaling (Fig. 1(4))
(Hou et al., 2011). It is still unclear whether the RNA PAMP ligand
translocates to the MAM still bound to RIG-I or if it is released upon
CARD tetramer formation. Moreover, it should be noted that though
MAVS ﬁlaments have been identiﬁed in cell-free extracts, their forma-
tion and presence have not been demonstrated in intact mammalian
cells in the context of virus infection (Hou et al., 2011). It is also noted
that LGP2 which lacks CARDs is thought to negatively regulate RIG-I
through interactions of the RD (Komuro et al., 2008; Komuro and
Horvath, 2006; Saito et al., 2007), while other studies indicate a
positive regulatory role for LGP2 in RLR signaling (Bruns et al., 2014;
Goubau et al., 2014; Satoh et al., 2010). Muchwork has been focused on
understanding the regulation of RLR signaling pathway by various host
proteins and is reviewed elsewhere (Chiang et al., 2014; Eisenacher and
Krug, 2012; Komuro et al., 2008).
PAMP ligands of RIG-I
RIG-I recognizes PAMP RNA ligands based on a level of
speciﬁcity in terms of sequence composition, PAMP motif length,
ss or dsRNA, and the presence of 50 cap versus exposed
50triphosphate (50ppp). 50 capped RNA does not trigger RIG-I
signaling nor does RNA lacking exposed 50ppp or 50 diphospho-
sphate (50pp) (Fig. 2). dsRNA of o300 base pairs with blunt ends
containing a 50ppp moiety are ideal ligands for RIG-I, although the
minimal length has been shown to be 10 base pairs as long as no
mismatches exist near the blunt end (Hornung et al., 2006; Kato et
al., 2006, 2008; Pichlmair et al., 2006; Schmidt et al., 2009). RNA
panhandle or bulge/loop structures are stimulatory if the RNA
contains 50ppp and blunted 50 end (Marq et al., 2010). However,
recent studies have also reported RIG-I binding and activity in the
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Fig. 1. RIG-I signaling pathway. (1) In resting cells RIG-I is maintained in a resting state in the cytosol characterized by a ‘closed ﬁst’ conformation with the RD and CARD
domains folded over the helicase domain. Interactions with LGP2 may be important for regulating RIG-I. (2) Upon recognition of an RNA ligand containing PAMP motif and
exposed 50ppp RIG-I is ubiquitinated and hydrolyzes ATP to promote a conformational change that holds the ligand PAMP RNA in the RNA binding groove of the RD.
(3) Interactions with PACT, ZAPS, TRIM25 and 14-3-3ε lead to formation of a RIG-I translocase that moves from a soluble compartment in the cell to the mitochondrial
associated membranes (MAM) where the complex engages MAVS for downstream signaling. The MAM is a specialized extension of outer mitochondria membrane (Mito)
and endoplasmic reticulum (ER) that form a synapse to create an innate immune signaling platform. (4) CARD–CARD interactions between RIG-I and MAVS then initiate
activation of the MAVS ‘signalosome’ which includes TRAF2, 3, and 6, TRADD, TANK, the IRF3 kinases TBK1 and/or IKKε, and the NF-κB kinase complex. (5) Signaling through
these kinases activates IRF3 and NF-κB. (6) Phosphorylated IRF3 and activated NF-κB translocate to the nucleus and initiate transcription of genes encoding products with
antiviral, proinﬂammatory, and immune-regulatory actions.
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presence of RNA containing 50pp moiety (Goubau et al., 2014; Lu et
al., 2010). It is possible that a signiﬁcant difference in the on–off
rate of the PAMP RNA binding to RIG-I containing different 50
moieties could explain this discrepancy (Lu et al., 2010; Wang et
al., 2010). Two signiﬁcant crystal structures have been solved to
reveal how RIG-I binds to different RNA species and has provided
insights into the conformational changes required for signaling
(Jiang et al., 2011; Luo et al., 2011). RIG-I has also been shown to
recognize speciﬁc sequences found in viral genomes, such as the
poly-U/UC motif found in the 30 untranslated region of hepatitis C
virus or the mRNA of the N gene of Hantaan virus (Fig. 2) (Lee et
al., 2011; Runge et al., 2014; Saito et al., 2008; Schnell et al., 2012).
Some controversy exists surrounding the ability of RIG-I to bind to
single-stranded RNA (ssRNA) synthesized using the T7 polymer-
ase, which has a tendency to add a short double-stranded copy-
back section to 50ppp ssRNA (Cazenave and Uhlenbeck, 1994).
When one such ssRNA was puriﬁed to remove any contaminating
dsRNA, it failed to stimulate RIG-I dependent signaling in vitro
(Marq et al., 2010; Schlee et al., 2009). However, production of
50ppp RNA itself by T7 polymerase is not sufﬁcient to produce a
PAMP. Such transcripts produced from a variety of templates do
not induce RIG-I signaling (Cui et al., 2008; Saito et al., 2008;
Schnell et al., 2012). Thus, despite a number of high resolution
crystal structures and excellent reports describing structural and
sequence determinants for RIG-I ligands, the true deﬁnition of a
RIG-I ligand remains controversial. The ﬁeld has collected a large
amount of information about what RNA structures or sequences
may be beneﬁcial for RIG-I binding and what may be sufﬁcient
for RIG-I signaling, but it remains difﬁcult to predict RIG-I
binding sequences and stimulatory RNA motifs based on struc-
ture and sequence. Deﬁning PAMP ligands of RIG-I thus requires
a comprehensive assessment of direct binding to RIG-I, PAMP
stimulation of RIG-I ATPase activity and conformation change, as
well as ability of PAMP stimulation to drive the cytosol-to-MAM
RIG-I ligand structures
ppp
Measles virus leader RNA
3’ UTR 5’ UTR
Influenza Virus NS1
PAMP
3’ leader 5’ trailer
SENV DI PAMP
SENV DI genome 546 nt
ppp
Hantavirus N mRNA
ppp
pp
Reovirus genomic RNA
Fig. 2. Examples of known RIG-I PAMP RNAs with models of speciﬁc structures shown. (A) RNAfold predicted structure of measles virus leader RNA using Edmonson B strain
sequence. (B) Inﬂuenza virus PAMPs found at genomic 50 and 30 nontranslated regions of the NS1 segment (adapted from Davis et al. (2012)). (C) Sendai virus defective-
interfering (DI) particle structure (adapted from Martinez-Gil et al. (2013)). (D) RNAfold predicted structure of Hantavirus nucleoprotein mRNA using TPM strain sequence.
(E) Reovirus genomic dsRNAwith 50pp motif identiﬁed as RIG-I PAMP in Goubau et al. (2014). (F) Hepatitis C virus genome with 30 nontranslated region and poly-U/UC PAMP
highlighted (adapted from Horner and Gale (2013)).
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translocation of RIG-I to mediate MAVS interaction and down-
stream intracellular signaling. The following sections provide an
overview of RIG-I interaction with viruses from different genera
that reveal shared and unique features of RIG-I interaction
among diverse virus families.
RIG-I recognition and regulation of innate immunity
Negative-sense ssRNA viruses
Bornaviridae
Bornaviruses are the only members of the order mononegavir-
ales, viruses with ssRNA negative sense genome, which replicate
and transcribe its genome exclusively in the nucleus of infected
cells, while assembly occurs in the cytoplasm. Bornaviruses estab-
lish persistent infection in the host in the absence of an IFN
response. RNA genomes isolated from virus preparations revealed
uniformly trimmed 50 termini, indicating that ‘genome trimming’
occurs efﬁciently during replication (Schneider et al., 2007). This
‘genome trimming’ removes nucleotides from the 50 end and could
function to regulate transcription and replication during periods of
persistence. Importantly, this trimming leaves a terminal 30 over-
hang during circularization for replication and also converts 50ppp
to 50p, thus evading recognition by RIG-I and avoiding the antiviral
actions of the innate immune response.
Borna disease virus (BDV) has been shown to actively antag-
onize the innate immune signaling pathway that leads to IRF3
activation. Unterstab et al. (2005) demonstrated that the BDV P
protein antagonizes TBK1 to prevent IFNβ induction during infec-
tion. The viral P protein can bind directly to TBK1 and prevent its
kinase activity in vitro. It is hypothesized that the ability to
prevent transcription of IRF3-dependent genes during viral infec-
tion, thus evading the effects of activating RLR pathway, is a key
element to establishing persistent infection in the mammalian and
avian host (Reuter et al., 2010).
Filoviridae
Members of the ﬁlovirus family include the human pathogens
Ebola and Marburg viruses that can cause severe hemorrhagic fevers
and high case-fatality ratios. The importance of the pro-inﬂammatory
response in controlling Ebola virus (EBOV) infectionwas demonstrated
by pre-activation of RIG-I in cells by treatment with RIG-I agonist RNA
prior to virus challenge. These cells were then resistant to EBOV
infection (Spiropoulou et al., 2009). Because stimulation of RIG-I leads
to a general pro-inﬂammatory response through induction of IFNs, it is
not clear what speciﬁc cellular antiviral effector mechanisms were
responsible for the protection against EBOV observed in this study.
Moreover, EBOV has been shown to encode an innate immune
antagonist protein, VP35. This viral protein was ﬁrst identiﬁed as an
antagonist of IFN induction (Basler et al., 2000). Subsequent reports
have suggested possible mechanisms for this inhibition including
sequestration of viral dsRNA through interactions with the VP35
RNA binding domain that prevent PAMP recognition by RIG-I
(Cardenas et al., 2006), inhibition of phosphorylation of IRF3/7 through
interactions with TBK1 (Basler et al., 2003; Hartman et al., 2008; Prins
et al., 2009), and direct interaction with RIG-I to suppress RIG-I
signaling activity (Luthra et al., 2013). While these studies suggest
that EBOV dsRNA might harbor PAMP motifs for RIG-I recognition and
innate immune signaling, the potential for RIG-I actually sensing the
EBOV genome has yet to be directly examined. It is possible that the
dsRNA sequestered by VP35 would trigger RLR signaling activation
during infection but the absolute nature of this putative PAMP is not
known (Ramanan et al., 2012).
Paramyxoviridae
RIG-I, as well as MDA5, has been reported to induce IFN
following infection of human cells with measles virus (Ikegame
et al., 2010). The viral leader transcript of the measles virus has been
identiﬁed as a potential PAMP ligand of RIG-I (Fig. 2) (Plumet et al.,
2007). However, during viral infection, limited IFN is detected in the
supernatant of infected cells, suggesting that measles virus may
antagonize RIG-I signaling actions. Originally, the V proteins of
paramyxoviruses were identiﬁed as MDA5 antagonists, preventing
Table 1
Summary of RIG-I recognition and antagonism by RNA viruses.
Virus Predicted RIG-I ligand(s) Evasion mechanism(s) References
ssRNA viruses
Negative sense
Bornaviridae Viral mRNA or replication
intermediates
50 genome trimming (Schneider et al., 2007)
TBK1 antagonism (Unterstab et al., 2005)
Filoviridae virion dsRNA Sequestration of dsRNA by VP35 (Basler et al., 2003; Cardenas et al., 2006)
Paramyxoviridae 50 trailer sequence Facilitates LGP2 interaction with RIG-I (Childs et al., 2012; Plumet et al., 2007)
Rhabdoviridae Unknown Unknown
Arteriviridae Unknown Deubiquitination of RIG-I (van Kasteren et al., 2012)
Arenaviridae Unknown 50ppp overhang RNA may be RIG-I sink (Marq et al., 2011)
Z protein-RIG-I antagonism (Fan et al., 2010)
Bunyaviridae
Hantavirus Viral mRNAs TBK1/IRF3 dephosphorylation (Alff et al., 2006; Cimica et al., 2014; Lee et al.,
2011)
Nairovirus Unknown Deubiquitination of RIG-I (van Kasteren et al., 2012)
Phlebovirus Unknown TBK1/IKKε sequestration (Ning et al., 2014)
Orthomyxoviridae Genomic RNA (30 NTR) Prevents RIG-I Ubiquitination Cap-snatching host Translational
shutoff
(Davis et al., 2012; Pichlmair et al., 2006)
Positive sense
Coronaviridae Unknown Deubiquitination of RIG-I, STING, TBK1, TRAF (Chen et al., 2014; Sun et al., 2012)
Suppression of PACT (Siu et al., 2014b)
Flaviviridae
Hepacivirus Genomic RNA (30 NTR) MAVS cleavage (Meylan et al., 2005; Saito et al., 2008)
Flavivirus Unknown Interferes with IFN pathway (Nasirudeen et al., 2011)
Togaviridae Unknown Host translational shutoff (Frolova et al., 2002)
dsRNA viruses
Reoviridae 50pp genomic RNAs Phosphohydrolase trimming of 50ppp (Goubau et al., 2014)
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its activation and thereby suppressing innate immune signaling
during infection (Childs et al., 2007, 2009; Lo et al., 2012; Motz
et al., 2013). Interestingly, a recent study shows that a single amino
acid difference between RLRs determines the ability of paramyx-
ovirus V proteins to suppress MDA5 versus RIG-I (Rodriguez and
Horvath, 2013). In 2012, Childs et al. (2012) reported that the V
protein of the related parainﬂuenzavirus type 5 (PIV5) interacts
with LGP2 to regulate the activation of RIG-I. They reported a
synergism between PIV5 V protein and LGP2 to inhibit RIG-I
activation when cells were exposed to known RIG-I PAMP ligands.
Childs et al. (2012) demonstrated that interaction between LGP2
and RIG-I occurred only in the presence of PIV5 V protein and not
the P protein, suggesting that LGP2 inhibition of RIG-I was a result
of V protein interference. However, others reported no inhibitor
effect on RIG-I activity in the presence of physiologically relevant
levels of V proteins from measles virus and PIV5 (Rodriguez and
Horvath, 2014). Because LGP2 can regulate RIG-I and MDA5 in
opposing ways, it has been difﬁcult to tease out the importance of
LGP2 interference with RIG-I activation and innate immune stimu-
lation by paramyxovirus V protein interactions. Thus, further
studies are warranted to deﬁne the role of LGP2 for RLR and innate
immune regulation in paramyxovirus infection.
Sendai virus (SenV) activates RIG-I signaling and is often used in
the ﬁeld as a model virus to stimulate robust type I interferon
responses through RIG-I activation. Recently, defective interfering
(DI) particles produced in SenV infection have been characterized to
robustly stimulate RIG-I activation and innate immune signaling,
likely explaining the nature of the viral agonists of RIG-I as products
of DI particles (Baum et al., 2010). The dsRNA present in particles
derived from the Cantell SenV strain is 546 nucleotides in length
and contains perfectly complementary ends, creating a hairpin
structure with a 50ppp that can function as a RIG-I-stimulatory
RNA (Fig. 2) (Kolakofsky, 1976). A recent report describes the use of
this stimulatory viral RNA as a vaccine adjuvant that can enhance
the immunogenicity of inﬂuenza A virus vaccination in a mouse
model, further demonstrating that RIG-I signaling drives immune-
enhancing actions against virus infection (Martinez-Gil et al., 2013).
Rhabdoviridae
The rhabdovirus vesicular stomatitis virus (VSV) has been demon-
strated to trigger RIG-I speciﬁc innate immune signaling during
infection (Furr et al., 2010; Kato et al., 2006). In RIG-I / mouse
embryonic ﬁbroblasts (MEFs), infection with VSV failed to induce
IFN-β expression compared to WT MEFs (Kato et al., 2006). Similar
results in RIG-I/ primary astrocytes indicate that RIG-I recognition
of viral RNA is essential for innate immune signaling in cells of the
central nervous system (Furr et al., 2010). While the exact RNA PAMP
of VSV that is recognized and bound by RIG-I to initiate the innate
immune response is not known, sequence similarity of the 50 leader
segment of the VSV genome to other known viral RIG-I ligands
suggests that this may be a stimulatory RNA motif (Saito et al., 2008).
Arteriviridae
Arteriviruses establish infections in horses, pigs and non-
human primates causing a wide-range of disease states including
edema, respiratory distress, and hemorrhagic fever. Arteriviruses
are actually positive-sense RNA viruses. Arteriviruses were shown
to be primarily recognized by MDA5 in MEFs (van Kasteren et al.,
2012). However Arteriviruses encode a deubiquitinase (DUB)
activity within their nonstructural protein 2 (nsp2) that serves to
catalyze the removal of ubiquitin chains from MDA5 (and RIG-I)
that otherwise facilitate RLR activation. This process results in
attenuation of MDA5 signaling and overall suppression of down-
stream IRF3 nuclear localization and IFN-β expression, thus
supporting viral replication and spread (Luo et al., 2008). Innate
immune evasion was linked to the nsp2 of porcine respiratory and
reproductive syndrome virus (PRRSV), which was sufﬁcient to
inhibit virus-induced IRF3 activation when expressed in target
cells (Li et al., 2010a). Viral DUB activity is conserved among
arterivirus strains and is linked with pathogenesis (van Kasteren et
al., 2012).
Arenaviridae
Arenaviruses contain a bipartite ambisense genome in which the
two termini are either exactly complimentary or contain two mis-
matches at nucleotide positions 6 and 8 (Albarino et al., 2009).
Interestingly, arenavirus genome synthesis initiates with a GTP at
position þ2 and the initiating 50pppG is realigned to form
50pppGpCOH before the replication primer is extended (Garcin and
Kolakofsky, 1992). Marq et al. (2010) demonstrated that the 50 RNA
overhang resulting from this ‘prime and realign’ mechanism of
replication signiﬁcantly decreases IFN-β expression compared to
RNA with no overhang. Further, the mismatched base pairings could
also contribute to a reduction in innate immune signaling and
elimination of the 50ppp completely eliminated IFN-β expression
(Marq et al., 2010). Ligand competition assays revealed that the 50ppp
overhang RNA acted as a sink for RIG-I, holding it tightly, but not
allowing for subsequent signaling (Marq et al., 2011). In this way, it is
thought that arenaviruses are recognized by RIG-I and that they are
able to actively antagonize RIG-I signaling to evade the innate immune
response.
New world arenaviruses have evolved the ability to prevent
RIG-I association with MAVS during infection. Huang et al. (2012)
reported a signiﬁcant decrease in IFN-β production in RIG-I
knockout cells infected with Junin Virus, with complete abrogation
of ISG expression. The Z proteins of new world arenaviruses, but
not old world arenaviruses, were shown to co-localize with RIG-I
and could co-immunoprecipitate RIG-I in vitro (Fan et al., 2010).
This association with RIG-I was sufﬁcient to block RIG-I–MAVS
interactions and NF-κB and IRF3 activation. However, most human
infections with pathogenic arenaviruses are known to involve high
levels of IFN expression and pro-inﬂammatory cytokines. Thus,
RIG-I antagonism must be incomplete during the course of in vivo
infection. Understanding the mechanisms underlying pathogenic
arenavirus infection and RIG-I antagonism will be essential to
development of novel therapeutics to treat increasingly common
zoonotic infections in humans.
Bunyaviridae
Hantavirus. Hantaviruses are members of the Bunyaviridae family,
which is comprised of more than 350 viruses, of which Hantaviruses
and Phleboviruses, as well as other genera are signiﬁcant human or
agricultural pathogens. Hantaviruses are transmitted by respiratory
route while phleboviruses are transmitted by the bite of an insect
vector (Horne and Vanlandingham, 2014). The hantavirus genome
consists of three negative-sense, single-stranded genome segments
which form blunt-ended panhandle structures containing a 50
monophosphate (50p) motif (Garcin et al., 1995; Wang et al., 2011).
Studies of hantavirus revealed that this 50p motif prevents RIG-I
recognition of the genomic RNA (Habjan et al., 2008; Wang et al.,
2011). However, during infection, RIG-I is required for innate immune
signaling (Lee et al., 2011). Lee et al. (2011) demonstrated that the viral
N gene from Hantaan virus (an Old World hantavirus) could serve as a
ligand for RIG-I when transfected in a mammalian expression vector,
suggesting that viral mRNAs could serve as the stimulatory RNA in
hantavirus infection. The authors concluded that themRNA from the N
gene contained double-stranded RNA recognized by RIG-I because co-
transfection of the N gene with the E3 gene from Vaccinia virus, which
sequesters dsRNA, resulted in ablation of innate signaling (Fig. 2) (Lee
et al., 2011). Further elucidation of the structural motif recognized by
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RIG-I should complement similar studies to determine whether other
hantavirus mRNAs are also recognized by RIG-I, and the elucidate the
role of 50 phosphates in this process.
RIG-I activation is inhibitory to hantavirus replication, and hanta-
viruses have evolved mechanisms to inhibit the inﬂammatory
response induced by RIG-I signaling. Interestingly, the N protein
from Andes virus (a New World hantavirus) has been implicated in
suppressing the RIG-I signaling pathway (Cimica et al., 2014). Cimica
et al. (2014) demonstrated that expression of the N protein inhibited
IFN-β and ISG expression in the presence of a constitutively active
RIG-I protein and that this inhibition occurs by blocking downstream
activation of TBK1 and phosphorylation of IRF3. In addition to the N
protein, Alff et al. (2006) showed that the cytoplasmic tail of the viral
G2 protein could bind cellular protein kinases and prevent phos-
phorylation of TBK1. Importantly, the G2 cytoplasmic tail of human
pathogenic hantaviruses was found to exhibit this function, whereas
the G2 cytoplasmic tail of non-pathogenic hantaviruses did not (Alff
et al., 2006). The presence of redundant mechanisms for inhibition of
RIG-I-dependent signaling suggests that this pathway presents a
strong selective pressure on the virus.
Phlebovirus. The speciﬁc roles of RIG-I and MDA5 in phlebovirus
recognition are not well deﬁned but the importance of this RLR
pathway is exempliﬁed in the active antagonism by the nonstructural
protein (NSs) of severe fever with thrombocytopenia syndrome virus
(SFTSV) (Ning et al., 2014). Ning et al. (2014) demonstrated that NSs
binds and sequesters the components of the TBK1/IKKε complex to
prevent activation of IRF3 for downstream innate immune signaling
induced by the RLRs. Therefore, RLR recognition and activation must
be a strong pressure on phleboviruses leading to the evolution of
speciﬁc evasion strategies. Further, research must focus on
understanding how each RLR is involved in recognition and what
viral RNA species is recognized as PAMP by each RLR.
Nairovirus. Nairoviruses are members of the family Bunyaviridae
that contain negative-sense, single-stranded circular genomes. The
viral RNA is not recognized by RIG-I due to the lack of a free 50 or 30
end. However, nairoviruses, like arterviruses, encode DUB enzymes
that deubiquitinate RIG-I to prevent innate immune signaling
activation (van Kasteren et al., 2012), suggesting that during
nairovirus infection/replication a PAMP, likely a viral transcription
product, is produced that can activate RIG-I. The RIG-I-stimulatory
PAMP RNA involved in triggering RIG-I signaling remains undeﬁned.
Orthomyxoviridae
The Orthomyxoviridae include Inﬂuenza A, B, and C viruses. The
viruses harbor a negative sense multi-segmented single stranded RNA
genome. Inﬂuenza A virus (IAV) encodes 8 genome segments and
represents the major epidemic and pandemic virus of past and recent
time (Iwasaki and Pillai, 2014; Palese, 2004). IAV is maintained in
water fowl and other avian species and is typically transmitted among
encounters of domestic water fowl or chickens with pigs and humans
wherein reassortment of viral genome segments in pigs co-infected
with multiple IAV strains can result in new viruses. When exposed to
humans, these new viruses cause contemporary seasonal epidemics or
in the worst outcome creates an IAV pandemic strain against which
the human population has little or no pre-existing immunity (Palese,
2004). Induction of an innate immune response by IAV occurs
differentially among strains owing to the fact that the virus directs a
variety of host response evasion strategies that impose limitations on
host cell gene expression, including 50 cap snatching activity, tran-
scriptional regulation, and evasion of RIG-I activation of innate
immune signaling (Schmolke and Garcia-Sastre, 2010). Early studies
revealed that the viral nonstructural protein NS1 could direct evasion
of IFN induction and host defenses during early infection through
direct interference or indirectly via interference with host mRNA
processing (Garcia-Sastre et al., 1998). Since then Pichlmair et al.
(2006) demonstrated that RIG-I recognizes 50ppp genomic ssRNA from
IAV during infection (Fig. 2). This was the ﬁrst demonstration, that
RIG-I could recognize both dsRNA and ssRNA in a virus infection albeit
via 50ppp. Further studies identiﬁed the 30 nontranslated region of the
viral genome as a ligand for RIG-I independent of the 50-ppp wherein
lariat structure of the viral RNA end provides a substrate for recogni-
tion by RIG-I (Davis et al., 2012). The IAV non-structural protein NS1
was shown to antagonize RIG-I signaling (Mibayashi et al., 2007) and
further shown to form a complex with RIG-I to suppress its function
(Pichlmair et al., 2006). This complex formation blocks TRIM25
ubiquitin E3 ligase-mediated Lys63-linked ubiquitination of RIG-I,
which is required for downstream signaling (Rajsbaum et al., 2012).
Interestingly, this inhibition by NS1 is species speciﬁc, suggesting that
this activity may be one of many required adaptations for host-species
jump of inﬂuenza viruses (Rajsbaum et al., 2012). Malur et al. (2012)
showed that NS1 from IAV strains that induce RIG-I activation can co-
opt LGP2 for inhibition of RIG-I signaling.
Other studies suggest that the proinﬂammatory response
triggered by RIG-I and TLR7 could actually be essential for efﬁcient
IAV replication (Pang et al., 2013). Pang et al. observed that viral
replication in mice deﬁcient for both MAVS and TLR7 was
signiﬁcantly reduced in the lung compared to wild-type mice.
This replication could be enhanced through addition of bronchial
lavages from wild-type infected mice, indicating that a robust
interferon and pro-inﬂammatory responses may be helpful for
viral replication. Indeed, the authors demonstrated that TLR7 and
MAVS-dependent signaling is required to recruit monocyte-
derived DCs to the lung and that these cells serve as target cells
for viral infection (Pang et al., 2013). Thus, a careful balance
between inﬂammatory signals that restrict viral infection and
sustained inﬂammation that enhances viral replication may deter-
mine IAV infection outcome in humans.
Positive sense RNA viruses
Coronaviridae
Both RIG-I and MDA5-dependent signaling has been shown to
play a role in innate immune defenses against murine hepatitis virus
infection (Li et al., 2010b). Experiments to knock down expression of
either MDA5 or RIG-I revealed that lack of either imposes a block in
virus-induced IFN-α/β production in murine oligodendrocyte cells (Li
et al., 2010b). However, the respective roles of each RLR in recogni-
tion and innate immune activation were not deﬁned. It remains
possible that each RLR is essential for recognition of viral RNA at
distinct stages during the infection as has been described for West
Nile virus (WNV) infection (Errett et al., 2013). Because the corona-
virus genomic RNA contains a 50 cap moiety known to block RIG-I
recognition of RNA, it is likely that replication intermediates or
negative sense subgenomic RNAs and not genome/virion RNA serve
as the stimulatory RNA for RIG-I during infection while MDA5 may
recognize the replicating genome dsRNA products.
As large RNA viruses, coronaviruses contain the genetic space to
encode for multiple proteins that interact with various factors in the
innate immune signaling pathway to evade the host response to
infection. Similar to arteriviruses, coronaviruses encode a protease
capable of inhibiting ubiquitination of important innate signaling
molecules to prevent induction of IFNs. For example, the SARS
coronavirus has been shown to encode a Papin-like protease
(PLpro) which inhibits IRF3 activation through deubiquitination of
RIG-I, STING, TRAF and TBK1 (Chen et al., 2014; Sun et al., 2012).
MERS-CoV protein 4a suppresses the RIG-I activator PACT in an
RNA-dependent manner to prevent RIG-I signaling (Siu et al.,
2014b). The M protein of SARS CoV has also been shown to interact
with RIG-I, TRAF, and TBK1 to prevent the interaction of TRAF with
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other downstream effectors for signaling IFN induction (Siu et al.,
2014a). Thus, coronaviruses encode multiple factors that direct a
variety of innate immune evasion strategies to support infection.
Flaviviridae
Members of the Flaviviridae are enveloped, positive sense
ssRNA viruses. The family includes ﬂaviviruses, hepacivurses, and
pestiviruses that cause disease in humans or agriculturally impor-
tant animals (Fields et al., 2013).
Flavivirus. Flaviviruses are arboviruses that are transmitted
between mosquito to birds within enzootic cycles that include
humans and other animals as dead-end hosts (Fields et al., 2013).
Various studies have shown that sustained IRF3 activity through
MAVS-dependent RLR signaling is essential for host protection
from WNV, an emerging ﬂavivirus (Errett et al., 2013; Suthar et al.,
2010).WNV is recognized by both RIG-I and MDA5, although the
PAMP that includes 50ppp for RIG-I recognition and dsRNA for
MDA5 recognition is not yet fully characterized (Errett et al., 2013).
Of interest is that the ﬂaviviruses are recognized as nonself in the
vertebrate host through the actions of both RIG-I and MDA5. Errett
et al. (2013) described distinct temporal activity of each PRR
during WNV infection, with RIG-I recognition and activity
occurring early (less than12 h postinfection) and MDA5 activity
beginning late (greater than 24 h post-infection) wherein both
RLRs were important for host survival in vivo. The WNV virion
RNA contains a 50cap which is expected to mask the 50ppp
required for RIG-I recognition (Fields et al., 2013). Thus the likely
stimulatory RNA for RIG-I includes either a 50ppp replication
intermediate which may form dsRNA complexes or non-coding
subgenomic RNAs found during infection (Roby et al., 2014).
RIG-I activity is essential for survival of mice infected with the
Japanese encephalitis virus (JEV), a ﬂavivirus related to WNV (Kato
et al., 2006). RIG-I was also shown to mediate the inﬂammatory
response of neurons during infection which leads to the release of
pro-inﬂammatory cytokines that recruit immune cells to the brain
(Nazmi et al., 2011). The RNA ligand for RIG-I recognition of JEV is
unknown but, based on similarity to WNV, it is likely a replication
intermediate or subgenomic RNA marked by the presence of a
50ppp for RIG-I recognition.
Innate immune responses to Dengue virus (DENV) are thought
to involve RIG-I, MDA5, and TLR3 (Loo et al., 2008; Nasirudeen et
al., 2011). Loo et al. describe incomplete signal suppression in cells
lacking either RIG-I or MDA5, while DENV-induced innate immune
signaling was completely lost in cells lacking both RLRs. Thus, both
PRRs could be responsible for innate immune signaling during
acute DENV infection, perhaps operating in temporally distinct
fashion as in WNV infection (Loo et al., 2008). Similarly,
Nasirudeen et al. (2011) observed measurable IFNβ production in
individual knockdowns for RIG-I, MDA5, and TLR3, but triple
knockdown cells completely lost all innate immune signal during
DENV infection. DENV, like the other ﬂaviviruses, has not been
shown to antagonize the RLR signaling pathway directly but has
been shown to antagonize the IFN signaling JAK–STAT pathway
through degradation of STAT2 and other means recently reviewed
in Green et al. (2014).
Hepacivirus. Like their ﬂavivirus cousins, hepaciviruses are enveloped
ssRNA viruses. However, hepaciviruses are not arboviruses but instead
are transmitted among humans via parenteral exposure to blood or
blood products (Hajarizadeh et al., 2013). Hepatitis C virus (HCV) is the
major human pathogen in this virus family, which also includes the
related GB viruses (GBV), GBV-C through GBV-D, that do not cause
disease in humans (Fields et al., 2013; Stapleton et al., 2011). In 2005
RIG-I was identiﬁed as an essential host factor that mediates the
recognition of HCV RNA in hepatoma cell lines wherein RIG-I serves
to recognize and bind to the 30 nontranslated region of the HCV RNA
(Sumpter et al., 2005). This discovery was followed with identiﬁcation
of the viral poly-uridine/cytosine (poly-U/UC) motif in the 30
nontranslated region together with 50ppp of the viral genome as the
HCV PAMP (Fig. 2) (Saito et al., 2008; Uzri and Gehrke, 2009). The poly-
U/UC PAMP motif is marked by a U-core region that typically includes
17 or more poly-U nucleotides that are essential for PAMP recognition
such that U-core length and 50ppp are critical determinants of PAMP
activity and recognition of HCV RNA by RIG-I (Schnell et al., 2012).
When introduced in cells the poly-U/UC motif was shown to trigger
RIG-I signaling of innate immune defenses that could suppress HCV
infection (Saito et al., 2008). The induction of innate immunity by RIG-I
signaling is countered however during HCV infection through the
actions of the viral nonstructural (NS)3/4A protease that targets and
cleaves MAVS to suppress RIG-I signaling (Foy et al., 2003; Loo et al.,
2006). HCV most often mediates a chronic infection in people acutely
exposed to the virus, and NS3/4A cleavage of MAVS to inactivate the
RIG-I pathway has been linked to chronic infection progression in
models of HCV infection (Horner et al., 2012). The structural
requirements of RIG-I recognition of the HCV poly-U/UC and the viral
mechanisms of innate immune evasion have been thoroughly reviewed
previously (Horner, 2014; Horner and Gale, 2013).
Togaviridae
The family Togaviridae includes the Alphaviruses, which are
mosquito-transmitted viruses, and the Rubiviruses which are aerosol
acquired viruses. Togaviridae members are enveloped, positive sense
ssRNA viruses. Transcriptional proﬁling of human cells infected with
alphaviruses, such as Chikungunya (CHIKV) and Sindbis (SINV)
viruses, has shown a signiﬁcant transcriptional upregulation of innate
immune signaling genes, while host translation is shut off by the nsP2
viral protein to prevent protein production (Frolova et al., 2002) To
determine the source of pathogen recognition, Burke et al. (2009)
investigated IFN-α/β production in murine embryonic ﬁbroblasts
(MEFs) following infection with a mutant SINV unable to prevent
host protein synthesis. Infection in WT MEFs with the mutant SINV
led to IFN production. MDA5 / MEFs produced 2-fold less IFN
following infection with mutant SINV compared to WT MEFs (Burke
et al., 2009). In contrast, RIG / MEFs produced signiﬁcantly
increased levels of IFN following mutant SINV infection. While
Burke et al. (2009) conclude that these results indicate an important
role for MDA5 in SINV recognition and signaling, they acknowledge
the possibility that RIG-I exerts a signiﬁcant restriction on SINV
replication which would also explain these results. White et al.
(2011) demonstrated that infection of human ﬁbroblasts with CHIKV
induces IRF3 dimerization and nuclear localization that is MAVS-
dependent, consistent with MDA5 or RIG-I activation during infection.
Further elucidation of the viral region recognized by either RIG-I or
MDA5 and ﬁner resolution of the roles of each PRR are necessary to
determine the nature of pathogen recognition for the Togaviridae.
dsRNA viruses
Reoviridae
Members of this virus family are non-enveloped viruses that
harbor multiple segments of dsRNA as their genome. The 10 genomic
segments of the reovirus genome form blunt-ended hairpin struc-
tures but were thought to evade recognition by RIG-I by encoding a
phosohohydrolase that trims the 50ppp to 50 diphosphate (pp) (Fields
et al., 2013). However, a recent report by Goubau et al. (2014)
describes RIG-I recognition and activation induced by reovirus RNA
in vitro, and reveal that MAVS signaling is important for viral control
in vivo. This study demonstrated that 50pp can serve as a recognition
motif of PAMP RNA (Fig. 2). Although RIG-I signaling was evident in
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response to 50pp RNA treatment, the magnitude of RIG-I-induced IFN
production was signiﬁcantly greater following treatment with 50ppp
compared to 50pp RNA. Thus, while viral phosohohydrolase activity
to render 50pp reduces RIG-I signaling of innate immunity during
reovirus infection, it does not prevent PAMP recognition such that
innate immune signaling remains active but attenuated. The physio-
logical relevance of differential RIG-I signaling in response to 50ppp
versus 50pp motifs remains unclear in terms of immune response
induction and host control of virus infection.
Interestingly, resistance to grass carp reovirus (GCRV) has been
mapped to speciﬁc insertions and deletions found in the Carp RIG-I
gene homolog, further underscoring the importance of RIG-I protein
in reovirus recognition (Wan et al., 2013). These observations raise
the interesting possibility that changes in RIG-I protein composition/
structure between species have allowed for changes in PAMP
recognition proﬁle of RIG-I orthologs, thus reﬂecting differential
evolutionary pressures by reoviruses across species.
Setting the tone: RLR crosstalk leads to speciﬁc adaptive
response
PAMP recognition and pathogen recognition receptor signaling
and pathways inside the infected cell have profound effects on cell
survival, the control of cell to cell virus spread, and the onset of
effective host immunity. Often PRR signaling directs major alterations
in gene expression of the infected cell, thus programming the cell for
virus restriction or cell death. Additionally, PRR signaling does not
occur in isolation, but instead viral products trigger a variety of cell
signaling pathways that mediate crosstalk with one another to direct
synergistic or antagonistic actions toward controlling infection (Loo
and Gale, 2011). For example, RLR activation can function together
with TLR3 signaling leading to enhanced HLA-I cross-presentation of
antigen by dendritic cells (Lalwani et al., 2013). In contrast, activation
of the RLR pathway by poly(I:C) or 50ppp RNAwas shown to suppress
TLR-mediated transcription of IL12b during bacterial infection
(Negishi et al., 2012). This RLR signaling attenuated TH1 and TH17
responses leading to decreased survival of mice treated with a
sublethal dose of Lysteria monocytogenes. Such crosstalk may explain
how viral infection can exacerbate the symptoms of other microbial
infections. Other in vivo models of RNA virus infection have also
revealed the ability of the RLR pathway to program adaptive T cell
responses. Utilizing various RLR pathway knockout animals has
shown that CD4 and CD8 T cell responses can be severely dysregu-
lated in both a cell extrinsic and cell intrinsic manner (Lazear et al.,
2013; Suthar et al., 2010). Moreover, RNA virus infection has been
shown to induce inﬂammasome activation through MAVS (Delaloye
et al., 2009; Ermler et al., 2014; Pothlichet et al., 2013). Poeck et al.
(2010) revealed that RIG-I may interact in a MAVS-dependent manner
with CARD9 and Bcl-10 to activate NF-κB for transcription of IL-1β
and other factors involved in inﬂammasome activation and onset of
the inﬂammatory response to virus infection. In addition, MAVS has
been shown to interact with NLRP3 and direct association with the
MAM and facilitate NLRP3 oligomerization leading to caspase-1
activation and release of mature IL-1β to drive the inﬂammatory
response (Park et al., 2013). Regulation of apoptosis and
inﬂammasome-induced cell death or pyroptosis through RLR/MAVS-
dependent activation of the inﬂammasome may have evolved as a
mechanism to prevent viral spread and induce a robust pro-
inﬂammatory immune response, thus linking innate antiviral immu-
nity with inﬂammatory signaling and responses that control virus
infection.
Further studies to understand the outcome of PRR crosstalk and
RLR signaling will direct the design of novel adjuvants or ther-
apeutics that could be used to trigger speciﬁc innate responses to
ﬁght viral infection. A number of groups have already explored the
use of RIG-I agonists to prevent viral infection. RIG-I activation
using 50ppp RNA can restrict viral infection when treatment occurs
before or after virus challenge in vitro and in vivo (Chen et al.,
2013; Han et al., 2011; Spiropoulou et al., 2009). Others have
already developed RIG-I agonists which can activate the pro-
inﬂammatory response in the absence of stimulatory RNA
(Goulet et al., 2013; Han et al., 2011), and small molecule RIG-I
agonists are being developed as antivirals to suppress RNA virus
infection (Bedard et al., 2012). These studies present proof of
concept that stimulation of a speciﬁc innate immune responses
alone or combined with the presentation of viral antigen or
targeted vaccine design could lead to broad spectrum antiviral
strategies as therapy for RNA virus infection, as well as providing
adjuvant actions for enhancement of RNA virus vaccines.
Conclusions
Detection of non-self nucleic acid PAMPs is essential for cellular
and systemic host defense against viral pathogens. The innate
antiviral immune response initiated by RIG-I activation serves to
program a speciﬁc adaptive immune response effective against RNA
viruses. In addition, cross-talk between the RLR pathway and other
cellular PRR pathways can skew the host response towards toler-
ance or defense against invading pathogens. RIG-I plays a key role in
the defense against RNA viruses from broad genera. RNA viruses
have evolved mechanisms for either evading recognition by RIG-I or
active antagonism of RIG-I signaling (Table 1). However, beyond
50ppp the characteristics of RIG-I ligands remain poorly understood.
Future studies must focus on deﬁning the speciﬁc RNA species,
sequence and structure recognized by RIG-I during virus infection,
and on assessing the conservation of such properties among RNA
virus genera. Deﬁning the characteristics of RIG-I ligands and the
diverse effects on the innate and adaptive immune response when
multiple PRR pathways interact is essential for informing design of
novel therapeutics or adjuvants tailored to speciﬁc RNA virus
pathogens.
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